In addition to helping enhance affordability of ARV drugs, the company also has helped increase access to these medications by introducing a number of ARV innovations, for instance producing single blister "combo" packs, which provide a reduced pill burden and once-a-day dosage. Mylan also developed three FDA/WHO-approved heat-stable ARV products, which can be distributed and used in warm climates where refrigeration infrastructure is not widely available. In addition, Mylan has been a global leader in producing ARV formulations for pediatric use.According to WHO, HIV is one of the world's leading infectious killers, claiming more than 25 million lives over the last 30 years. In 2011, there were approximately 34.2 million people living with HIV. Today, approximately one-third of all people in the developing world receiving treatment for HIV/AIDS are taking a Mylan product.
Mylan Commemorates 24th World AIDS Day
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts